After Vioxx, What Next?

The Scientist Releases Supplement Laying Out Blueprint for Pain Research(Philadelphia, PA - April 7, 2005) In an era of increased scrutiny on the prescribing of opiates in the United States, the withdrawal of Vioxx - and today Bextra - from the US market, and the growing awareness of the debilitating effects of widespread chronic pain around the world, The Scientist is proud to present a new supplement, Pain, an in-depth look at what's next for pain research and treatment.According to


Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

(Philadelphia, PA - April 7, 2005) In an era of increased scrutiny on the prescribing of opiates in the United States, the withdrawal of Vioxx - and today Bextra - from the US market, and the growing awareness of the debilitating effects of widespread chronic pain around the world, The Scientist is proud to present a new supplement, Pain, an in-depth look at what's next for pain research and treatment.

According to the National Institutes of Health, 100 million people in the United States suffer from chronic pain, costing about $79 billion a year in care and lost work time. Biomedical research is inching ever closer to an understanding of the maddeningly subjective but nearly universal experience. Now, The Scientist offers its unique brand of coverage to call to attention to what has been done and what remains unanswered halfway through the congressionally mandated decade of pain.

"With the Vioxx ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino

Products

Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio
Inventia Life Science

Inventia Life Science Launches RASTRUM™ Allegro to Revolutionize High-Throughput 3D Cell Culture for Drug Discovery and Disease Research

An illustration of differently shaped viruses.

Detecting Novel Viruses Using a Comprehensive Enrichment Panel

Twist Bio